RBC Capital Markets has revised its outlook for Galderma following the company's record H1 2026 sales of $3.13 billion and raised full-year guidance. The upgrade reflects strong execution across the injectables portfolio and accelerating demand in key markets.
Business & M&A
RBC Lifts Galderma Outlook Following H1 Beat
Analyst follows suit on revised guidance after record first-half sales.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
RBC revises Galderma estimates upward following record H1 sales and raised full-year guidance.
Galderma's ability to raise guidance mid-year signals confidence in sustained momentum through 2026, particularly in toxin and filler categories where GLP-1 weight-loss trends are driving both preventive and corrective aesthetic demand. For practice owners, analyst upgrades matter: they typically precede increased R&D investment, new product launches, and more aggressive rebate programs as manufacturers compete for market share. RBC's move suggests the Street expects Galderma to maintain pricing power and volume growth despite competitive pressure from AbbVie and Evolus.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.